Clinical trials: Acute Ischemia
Acute Ischemic Stroke, Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions
The objective of this study is to collect safety and effectiveness data on the Penumbra System reperfusion catheters in participants with isolated primary non-dominant and distal M2 occlusions who undergo endovascular mechanical…
- Trial name
- NCT07749170
- Testing
- Endovascular Thrombectomy, Medical Management
- Where
- 7 sites in United States
- Volunteers
- 250 people
- Sponsor
- Penumbra Inc.
Acute Coronary Syndrome
MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial
This study will be a proof-of-concept, placebo-controlled, double-blind, randomized trial in participants with a recent acute coronary syndrome (ACS) to evaluate the efficacy, pharmacokinetics, safety, tolerability, disease…
- Trial name
- PILOT (NCT02678923)
- Testing
- MDCO-216
- Where
- 20 sites in Canada, Czechia and 3 more
- Volunteers
- 126 people
- Sponsor
- The Medicines Company
Ischemic Stroke
European Registry on the ACE Reperfusion Catheters and the Penumbra System in the Treatment of Acute Ischemic Stroke
Prospective, single-arm, multicenter, observational registry of the ACE Reperfusion Catheters and the Penumbra System in Europe.
- Trial name
- PROMISE (NCT02678169)
- Testing
- Penumbra Aspiration System
- Where
- Germany
- Volunteers
- 204 people
- Sponsor
- Penumbra Inc.
Ischemic Stroke
Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy
The purpose of this study is to evaluate the efficacy and safety of long-term sequential therapy with Mexidol® in long-term sequential treatment of patients in the acute and early recovery periods of hemispheric ischemic stroke…
- Trial name
- EPICA (NCT02793687)
- Testing
- Mexidol
- Where
- 11 sites in Russia
- Volunteers
- 150 people
- Sponsor
- Pharmasoft
Myocardial Infarction
A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction
The purpose of the trial is the analysis of safety and efficacy of the chymase inhibitor BAY1142524 at a dose of 25 mg BID in comparison to placebo using a 6 months treatment period in patients with left-ventricular (LV)…
- Trial name
- CHIARA MIA 2 (NCT02976467)
- Testing
- Fulacimstat (BAY1142524)
- Where
- 25 sites in Czechia, Germany and 3 more
- Volunteers
- 107 people
- Sponsor
- Bayer
Ischemic Stroke
A Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Stroke
The purpose of this study is to assess the safety and the effectiveness of the Adaptive Tip Catheter (ATC) used as a first line direct aspiration thrombectomy technique for patients suffering of an acute ischemic stroke.
- Trial name
- PHAST (NCT07367100)
- Testing
- Adaptive Tip Catheter
- Where
- 10 sites in Belgium, France and 1 more
- Volunteers
- 74 people
- Sponsor
- Neuravi Limited
Ischemic Stroke
Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke
The purpose of this study is to evaluate the efficacy and safety of intravenous doses of 3K3A-APC, a recombinant variant of human activated protein C (APC), in the treatment of acute ischemic stroke following treatment with…
- Trial name
- RHAPSODY-2 (NCT05484154)
- Testing
- 3K3A-APC
- Sponsor
- ZZ Biotech, LLC
Acute Myocardial Infarction
SpinChip Hs-cTnI Determination of the 99th Percentile URL
During a heart attack, the protein troponin I is released from the heart muscle into the bloodstream. Measurements of cardiac troponin in blood are used as an aid in the diagnosis of heart attack.
- Trial name
- HEAT-3 (NCT06463275)
- Testing
- SpinChip hs-cTnI
- Where
- 4 sites in Sweden
- Volunteers
- 1,355 people, healthy volunteers welcome
- Sponsor
- SpinChip Diagnostics ASA
Acute Ischemic Stroke
A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
- Trial name
- ACT-IVATE (NCT07742098)
- Testing
- NTS-521
- Volunteers
- 140 people
- Sponsor
- NeuroTrauma Sciences, LLC
Myocardial Infarction
Safety and Efficacy Study of MGuard Stent After a Heart Attack
The goal of this study is to demonstrate the superiority of the MGuard™ stent over commercially-approved bare-metal (BMS) /drug-eluting stents (DES) in achieving better myocardial reperfusion in primary angioplasty for the…
- Trial name
- MASTER (NCT01368471)
- Testing
- MGuard, Control BMS or DES
- Where
- 7 sites in Poland, South Africa
- Volunteers
- 433 people, healthy volunteers welcome
- Sponsor
- InspireMD
Acute Coronary Syndrome
Canadian Ticagrelor Survey
This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns…
- Trial name
- NCT01757483
- Where
- Canada
- Volunteers
- 244 people
- Sponsor
- AstraZeneca
Cerebral Infarction
Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.
- Trial name
- NCT00200356
- Testing
- Edaravone, Sodium Ozagrel
- Volunteers
- 401 people
- Sponsor
- Shionogi
Atherosclerosis, Percutaneous Coronary Intervention
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
The study is designed to compare the efficacy and safety profile of cangrelor to standard of care in patients require percutaneous coronary intervention (PCI).
- Conditions
- Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- CHAMPION (NCT01156571)
- Testing
- cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor
- Where
- United States
- Volunteers
- 11,145 people
- Sponsor
- The Medicines Company
Acute Ischemic Stroke, Transient Ischemic Attack (TIA)
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
- Trial name
- AXIOMATIC-SSP (NCT03766581)
- Testing
- BMS-986177, Clopidogrel, Aspirin
- Where
- 424 sites in United States, Argentina and 27 more
- Volunteers
- 2,366 people
- Sponsor
- Bristol-Myers Squibb
Anemia, Sickle Cell, Sickle Cell Anemia
Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
Sickle Cell disease is caused by an inherited hemoglobin disorder. Healthy red blood cells are discoid and can deform and move through small blood vessels to carry oxygen to all parts of the body.
- Conditions
- Anemia, Sickle Cell, Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders
- Trial name
- NCT01925001
- Testing
- MP4CO, Sodium chloride solution
- Where
- 14 sites in Bahrain, Belgium and 7 more
- Sponsor
- Sangart
Cerebrovascular Accident
Safety and Efficacy of NeuroFlo in 8-24 Hour Stroke Patients
The purpose of this study is to assess the safety and feasibility of the NeuroFlo™ catheter in treating patients with ischemic stroke whose last time symptom-free was between 8-24 hours prior to treatment.
- Trial name
- Flo 24 (NCT00436592)
- Testing
- NeuroFlo™ Catheter
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 26 people
- Sponsor
- CoAxia
Ischemic Stroke, Acute
Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset
Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus…
- Trial name
- FRIDA-CT (NCT07324837)
- Testing
- non-immunogenic staphylokinase
- Where
- 17 sites in Russia
- Volunteers
- 990 people
- Sponsor
- Supergene, LLC
ACS (Acute Coronary Syndrome)
ADHERE-S (NIS Brilique)
noninterventional study investigating persistence and adherence on ticagrelor in ACS patients in Serbia
- Trial name
- NCT03444012
- Testing
- ticagrelor 90 mg
- Where
- 9 sites in Serbia
- Volunteers
- 269 people
- Sponsor
- AstraZeneca
Multiple Myeloma, Myelodysplastic Syndromes
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in all patients who are treated with it under the actual condition of use pursuant to the conditions of approval. 1.
- Trial name
- NCT02921802
- Where
- Japan
- Volunteers
- 4,626 people
- Sponsor
- Celgene
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.